MedTrace Logo

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

NCT06664775 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2025-10-06

No results posted yet for this study

Summary

The purpose of this clinical study is to assess the efficacy and safety of TachoSil compared to the widely known and used for \> 60 years local hemostatic product Surgicel Original as an adjunct to control mild to moderate soft tissue bleeding during surgery.

Conditions

Interventions

BIOLOGICAL

TachoSil

Adjunct to hemostasis

BIOLOGICAL

Surgicel Original

Adjunct to hemostasis

Sponsors & Collaborators

  • Corza Medical GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-02
Primary Completion
2026-03-31
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06664775 on ClinicalTrials.gov